Except for ageusia/anosmia, all clinical, analytical, and respiratory parameters improved considerably. When compared to baseline data, SpO2 substantially improved at week two  and PaO2/FiO2 markedly improved in the first two weeks. The baricitinib group had significantly reduced CRP and IL-6 levels. The gene discussed is IL6; the disease is Kallmann syndrome.